MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio

 MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio

MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio

Shots:

  • Vector’s acquisition is an all-stock transaction including its novel P-II drug candidate AAV-GAD evaluated for Parkinson’s Disease
  • The acquisition focuses on developing candidate AAV-GAD and providing novel treatments for neurological disorders
  • AAV-GAD is a gene therapy candidate delivering glutamic acid decarboxylase (GAD) gene, currently in P-II for Parkinson’s Disease and has also received FTD from the US FDA

Click here to read full press release/ article | Ref: MeiraGTx | Image: Ophthalmology Innovation Summit

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post